KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Invested Capital (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Invested Capital for 15 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 97.13% to $31.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $88.9 million, a 91.79% decrease, with the full-year FY2025 number at $31.1 million, down 97.13% from a year prior.
  • Invested Capital was $31.1 million for Q4 2025 at Supernus Pharmaceuticals, up from $11.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.3 billion in Q3 2022 to a low of $11.2 million in Q3 2025.
  • A 5-year average of $852.4 million and a median of $965.8 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 54.06% in 2021, then tumbled 97.13% in 2025.
  • Supernus Pharmaceuticals' Invested Capital stood at $1.2 billion in 2021, then dropped by 24.08% to $907.3 million in 2022, then increased by 7.3% to $973.6 million in 2023, then rose by 11.25% to $1.1 billion in 2024, then crashed by 97.13% to $31.1 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Invested Capital are $31.1 million (Q4 2025), $11.2 million (Q3 2025), and $1.1 billion (Q2 2025).